In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544).
IRAK4 is a serine-threonine protein kinase known to be present and active in the occurrence of certain immunity responses, inflammation disorders, and various cancers. Under the terms of this agreement, Kainos will study the therapeutic mechanism of action of KM10544 in solid cancers, blood cancers, and lymphoma while Emmaus will be responsible for the investigation and proof of target disease selection, efficacy, and safety.
In compensation for entering this agreement Kainos received $500,000 in cash and $500,000 in shares of Emmaus common stock. In turn, Emmaus has been granted rights of first negotiation for an exclusive license regarding products based on the intellectual property resulting from the agreement.
